SPECIAL REPORT: Riding the Biotech Economic Tsunami - Surfing to Safety or Wipeout?


May 20, 2009
37 Pages - SKU: DECR2272770
License type:
Table of Contents Related Reports
Executive Summary
Strategic Considerations
Stakeholder Implications
Overview
Public and Private Equity Financing
The IPO Downturn
VC Investment
Platform-Technology-Derived Therapeutic Companies
Therapeutic Platform Companies
Target-Based Therapeutic Companies
Increasing Trend Toward Research-Stage Development Programs
Mergers and Acquisitions
Products and Pipelines as Drivers for M&A
Platform Technologies as Drivers for M&A
Corporate Partnerships
Deal Structure and Assessing Deal Value
Target and Lead Discovery
Target Identification and Validation Deals
Target Identification and Drug Discovery Through Academic Alliances
Lead Discovery Deals
Lead Identification Deals
Target-Focused Screening
Library- and Chemistry-Focused Screening
Lead Optimization Deals
Medicinal and Fragment-Based Screening
Drug Delivery
Drug Profiling
Protein Optimization Deals
Molecular Diagnostics Deals
Therapeutic Platforms Deals
Protein Therapeutics and Monoclonal Antibodies
Nucleic-Acid-Based Therapeutics
Cell Therapy
Outlook for Biotech Investment and Trends
Tables
1. Biotechnology Initial Public Offerings, 2008
2. Blockbuster and Top-Selling Drugs Acquired Through Pharma-Biotech Acquisitions
3. Blockbuster and Top-Selling Drugs Acquired Through Biotech-Biotech Acquisitions
4. Select Target Discovery Corporate Partnerships, 2008
5. Select Academic Drug Discovery and Research Alliances, 2008
6. Select Lead Identification Corporate Partnerships, 2008
7. Select Lead Optimization Corporate Partnerships, 2008
8. Select Protein Optimization Corporate Partnerships, 2008
9. Select Molecular Diagnostics Partnerships, 2008
10. Select Therapeutic Platform Corporate Partnerships, 2008
Figures
1. Biotech Quarterly Initial Public Offerings and Venture Capital Investments, 2002-2008
2. Life-Sciences-Related Venture Capital Investments, 2008
3. Technology Focus of Biotech Series A Companies, 2008
4. Developmental Stage of Therapeutic Biotech Companies with Series A Investments, 2005 and 2008
5. Biotechnology M&As Worth More Than $100 Million, 2002-2008
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Biopharmaceuticals Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!